Cover Image
市場調查報告書

全球循環性癌細胞(CTC)及腫瘤幹細胞(CSC)市場:產業規模·市場佔有率與趨勢·分析與預測

Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018

出版商 Transparency Market Research 商品編碼 249547
出版日期 內容資訊 英文 74 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球循環性癌細胞(CTC)及腫瘤幹細胞(CSC)市場:產業規模·市場佔有率與趨勢·分析與預測 Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
出版日期: 2012年08月15日 內容資訊: 英文 74 Pages
簡介

循環性癌細胞技術(CTC),是可以在末梢血中分離的癌細胞的回復與分析的技術。CTC分析可以進行低侵襲時的轉移的早期發現。CTC的分子分析可以進行計劃且有效的治療。從血液中除去CTC,可以抑制手術以及治療後的轉移。

本報告提供全球循環性癌細胞(CTC)及腫瘤幹細胞(CSC)市場上技術,產業展望,市場規模,產業的成長率及市場趨勢等分析,CTC及CSC市場上近幾年的發展,市場參與企業的詳細的簡介,不同地區的市場分析等彙整,為您概述為以下內容。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 全球診斷市場概要
  • 診斷產業的SWOT分析
  • 癌症診斷市場現狀
  • CTC及CSC概要
    • 市場現狀
    • 未來的可能性
    • 成長機會
  • CTC及CSC研究的近幾年的躍進
  • CTC及CSC市場促進因素
  • CTC及CSC市場阻礙要素
  • CTC及CSC市場機會

第4章 循環性癌細胞(CTC)

  • 循環性癌細胞是什麼?
  • CTC發現的重要事項
  • CTC的生物學及特徵
  • CTC VS DTC
  • CTC濃縮法
  • 細胞搜索系統
  • CTC濃縮技術的優點與缺點
  • 診斷及檢測的CTC的利用
  • CTC檢測及分析相關預測
  • CTC及DTS的檢測的改善
  • 全球癌症罹患率的增加

第5章 腫瘤幹細胞(CSC)

  • 腫瘤幹細胞(CSC)是什麼?
  • 目前癌症診斷及治療
  • 癌症的發病
  • 轉移
  • 轉移連鎖
  • 轉移最受影響的部位
  • CTC VS DTC
  • 有轉移性疾病的患者的血液說明
  • CTC和CSC比較
  • EMT及EMT的3個層級
  • CSC的生物學
  • 幹細胞標誌物

第6章 競爭分析

  • CSC及CTC研究產品廠商的市場佔有率
  • CSC研究焦點
  • 癌症死亡人數預測
  • 美國的新的癌症患者預測:各類型(男性·女性)
  • DTC檢測的改善
  • 乳癌患者統計·資料
  • 原發性vs.轉移性疾病的CTC的調查
  • 市場調查受訪者層各不同地區分佈
  • 腫瘤幹細胞(CSC)標誌物,惡性腫瘤及多重標誌物簡介
  • 市場分析·手法

第7章 地區分析

  • 北美
  • 歐洲
  • 亞太地區

第8章 企業簡介

  • Johnson & Johnson
    • 企業概要
    • 成長策略
    • 近幾年的開發
    • SWOT分析
  • Abbott Laboratories
  • Bristol-Myers Squibb (BMS)
  • Dexcom
  • Eli Lilly
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Lupin
  • Roche
  • Sanofi

圖表

目錄

Circulating tumor cell technology is an enabling technology for recovery and analysis of separated cancer cells in the peripheral blood. CTC technology offers advantages like high sensitivity, high specificity, reproducible, repeatable, and non-invasive diagnostic assay for guiding treatment decision and improved patient triage. Circulatory tumor cells (CTC) are cancer cells that get separated from the primary tumor or its metastases that circulate in the peripheral blood. Metastasis the major cause of cancer deaths and CTC may constitute seeds from metastases and indicate the spread of diseases. The circulating tumor cells' analysis will allow early detection of metastasis when it is less invasive. Molecular characterization of CTC enables the treatment to be planned effectively. Removing CTC from the blood will limit metastases after surgery or therapy.

Molecular characterization is significant from the point of view of developing new methodologies for CTC detection, isolation, enumeration, and subsequent genetic or proteomic analysis. Advancement in medical technologies is allowing efficient removal of CTC from circulation and has therapeutic potential.

This research report analyzes the Circulating tumor cells and cancer stem cells market from a technical as well as business perspective, describing the overall market size, industry growth rate, and market trends. It gives an analysis of the recent developments in CTC and CSC markets and includes detailed profiles of top industry players along with Porter's five force analysis. The report also analyzes all the micro and macro factors essential for the existing market players and new entrants along.

Major regions covered under this research study are North America, Europe, the Asia-Pacific, and the Rest of the World.

Reasons to Buy this Report

  • This research report will provide a forward perspective on market issues affecting market growth rate
  • It will help in understanding the competitive environment and make accurate and informed business decisions to withstand competition
  • The report will provide pin-point analysis of changing competition dynamics to keep one ahead of competitors
  • It will provide an in-depth analysis of key product segments and robust product segments
  • The research report provides a seven-year forecast on business projections and segmental behavior

Table of Contents

1. Introduction

  • 1.1. Key Objectives
  • 1.2. Report Description
  • 1.3. Scope and Definitions
  • 1.4. Research Methodology

2. Executive Summary

3. Market Overview

  • 3.1. Overview of Global Diagnostic Market
  • 3.2. SWOT Analysis of Diagnostic Industry
  • 3.3. Current Status of the Cancer Diagnostic Market
  • 3.4. Overview of CTC and CSC
    • 3.4.1. Current Status of the Market
    • 3.4.2. Future Potential
    • 3.4.3. Growth Opportunities
  • 3.5. Recent Breakthrough in CTC and CSC Research
  • 3.6. Drivers for CTC and CSC Market
  • 3.7. Restraints for CTC and CSC Market
  • 3.8. Opportunities for CTC and CSC Market

4. Circulating Tumor Cells (CTC)

  • 4.1. What are Circulating Tumor Cells
  • 4.2. Important Milestone in CTC Discovery
  • 4.3. Biology and Characteristics of CTCs
  • 4.4. CTC for Cancer Diagnostics
  • 4.5. CTCs Vs DTCs
  • 4.6. CTC Enrichment Methods
    • 4.6.1. PCR-based Analysis
      • 4.6.1.1. RT-PCR
      • 4.6.1.2. RT-qPCR
    • 4.6.2. Cytometric Analysis
      • 4.6.2.1. CellSearch
      • 4.6.2.2. LSC
      • 4.6.2.3. FAST
      • 4.6.2.4. Flow cytometry
      • 4.6.2.5. CTC-Chip
      • 4.6.2.6. Elispot
      • 4.6.2.7. FISH
  • 4.7. Cell Search System
  • 4.8. Advantages and Disadvantages of CTC Enrichment Techniques
  • 4.9. CTC Utility in Diagnosis and Detection
  • 4.10. Predictions made on CTC detection and analysis
  • 4.11. Improvements in the detection of CTCs and DTCs
  • 4.12. Worldwide Growth in the Prevalence of Cancer

5. Cancer Stem Cells (CSC)

  • 5.1. What are Cancer Stem Cell (CSCs)
  • 5.2. Current Cancer Diagnostics and Therapy
  • 5.3. Developing Cancer
  • 5.4. Metastasis
  • 5.5. Metastatic Cascade
  • 5.6. Mostly Affected Sites by Metastasis
  • 5.7. CTCs Vs DTCs
  • 5.8. Blood Description of patient with metastatic disease
  • 5.9. Comparison between CTCS and CSCs
  • 5.10. EMT and Three Classes of EMT
  • 5.11. Biology of CSCs
  • 5.12. Stem Cells Markers

6. Competitive Analysis

  • 6.1. Market Shares of Various CSC and CTC Research Products vendors
  • 6.2. CSC Research Focus
  • 6.3. Estimated Cancer Deaths, 2011
  • 6.4. New cancer cases by type (male and female) in the U.S., 2012 (estimated)
  • 6.5. Improvement in CTC Detection
  • 6.6. Breast Cancer Statistics and Facts
  • 6.7. Study of CTCs for primary vs metastatic disease
  • 6.8. Geographic Distribution of Market Survey Respondent Pool
  • 6.9. Cancer stem cell (CSC) markers, malignancies and
  • multimarker profiles
  • 6.10. Market Analysis and Methodologies

7. Geographical Analysis

  • 7.1. North America
  • 7.2. Europe
  • 7.3. Asia Pacific

8. Company Profiles

  • 8.1. Johnson & Johnson
    • 8.1.1. Company Overview
    • 8.1.2. Growth Strategy
    • 8.1.3. Recent Development
    • 8.1.4. SWOT Analysis
  • 8.2. Abbott Laboratories
    • 8.2.1. Company Overview
    • 8.2.2. Growth Strategy
    • 8.2.3. Recent Development
    • 8.2.4. SWOT Analysis
  • 8.3. Bristol-Myers Squibb (BMS)
    • 8.3.1. Company Overview
    • 8.3.2. Growth Strategy
    • 8.3.3. Recent Development
    • 8.3.4. SWOT Analysis
  • 8.4. Dexcom
    • 8.4.1. Company Overview
    • 8.4.2. Growth Strategy
    • 8.4.3. Recent Development
    • 8.4.4. SWOT Analysis
  • 8.5. Eli Lilly
    • 8.5.1. Company Overview
    • 8.5.2. Growth Strategy
    • 8.5.3. Recent Development
    • 8.5.4. SWOT Analysis
  • 8.6. GlaxoSmithKline
    • 8.6.1. Company Overview
    • 8.6.2. Growth Strategy
    • 8.6.3. Recent Development
    • 8.6.4. SWOT Analysis
  • 8.7. Glenmark Pharmaceuticals
    • 8.7.1. Company Overview
    • 8.7.2. Growth Strategy
    • 8.7.3. Recent Development
    • 8.7.4. SWOT Analysis
  • 8.8. Lupin
    • 8.8.1. Company Overview
    • 8.8.2. Growth Strategy
    • 8.8.3. Recent Development
    • 8.8.4. SWOT Analysis
  • 8.9. Roche
    • 8.9.1. Company Overview
    • 8.9.2. Growth Strategy
    • 8.9.3. Recent Development
    • 8.9.4. SWOT Analysis
  • 8.10. Sanofi
    • 8.10.1. Company Overview
    • 8.10.2. Growth Strategy
    • 8.10.3. Recent Development
    • 8.10.4. SWOT Analysis
Back to Top